Received Mar 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | Z004961 | — |
No adverse effects reported; received VARIVAX on 1/28/2026 and MMR II on 2/16/2026 which was 2 weeks early; This spontaneous report was received from a Nurse and referred to a 13-month-old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 28-Jan-2026, the patient was vaccinated with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) lyophilisate and solvent for solution for injection at 1 dosage form, total (single dose) for prophylaxis (lot number Z011895 was verified to be valid, expiration date: 17-Jul-2027) (injection site and route of administration not reported). The vaccine was reconstituted with sterile diluent (dose, lot number and expiration date not reported). On 16-Feb-2026, which was 2 weeks early, the patient was vaccinated with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) lyophilisate and solvent for solution for injection at 1 dosage form, total (single dose) for prophylaxis (lot number Z004961 was verified to be valid, expiration date: 24-Feb-2027) (injection site and route of administration not reported) (inappropriate schedule of product administration). The vaccine was reconstituted with sterile diluent (dose, lot number and expiration date not reported). No adverse effects reported. The action taken with the suspect vaccines was not applicable.
Sterile diluent